Showing results (31-40 of 652) with videos related to
Sort By:
Pageof 66
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Current status of gene therapy for lung cancer and head and neck cancerChulso Moon, Yun Oh, Jack A RothOncogene|April 24, 2002
Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cellsSeiichi Nakamura, Jack A Roth, Tapas MukhopadhyayCancer Research|May 6, 2004
Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cellsFutoshi Uno, Jiichiro Sasaki, Masahiko Nishizaki, et al.Clinical Lung Cancer|March 18, 2009
Neoadjuvant and intrapleural therapies for malignant pleural mesotheliomaAnne S Tsao, Reza Mehran, Jack A RothCancer Immunology Research|January 18, 2018
TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer ModelsIsmail M Meraz, Mourad Majidi, Xiaobo Cao, et al.Lung Cancer (Auckland, N.Z.)|February 18, 2017
Drug resistance in lung cancerManish Shanker, David Willcutts, Jack A Roth, et al.Oncogene|April 18, 2002
C-terminus of p53 is required for G(2) arrestSeiichi Nakamura, Yoshihito Gomyo, Jack A Roth, et al.Thoracic Surgery Clinics|August 13, 2013
Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery?Shervin M Shirvani, Joe Y Chang, Jack A RothSeminars in Oncology|March 15, 2002
Genetic and immunologic therapies for lung cancerStephen G Swisher, Jack A Roth, David P CarboneNature Reviews. Clinical Oncology|December 24, 2009
Surgery: Future directions in multimodality therapy for NSCLCAnne S Tsao, Jack A Roth, Roy S HerbstPageof 66